enGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq.
Read MoreBigBio Communications, publisher of Big4Bio, the premier aggregator of financial, clinical, and business news from the top life sciences regions, is proud to announce the upcoming launch of “BioStartup News” (biostartup.news), a weekly newsletter recapping the latest developments of U.S.-based life sciences startups.
Read MoreBigBio Communications, publisher of Big4Bio, the premier aggregator of financial, clinical, and business news from the top life sciences regions, is proud to announce the upcoming launch of “BioStartup News” (biostartup.news), a weekly newsletter recapping the latest developments of U.S.-based life sciences startups.
Read More“We are pleased to close our first financing and to welcome Frederic Ors as lead investor and strategic advisor to Saguaro. Frederic is a well-recognized executive with a track-record of successfully growing biotech companies,” said Louis Turcotte Co-Founder & Chief Executive Officer. “Frederic shares our vision on the potential of next-generation technologies to make drug discovery more successful and we are looking forward to benefit from his experience and network.”
Read MoreCompany founded in 2021 and led by Clarissa Desjardins, Ph.D., previously the founder and chief executive officer of Clementia Pharmaceuticals (now Ipsen). Kenneth J. Valenzano, Ph.D., joins as Chief Scientific Officer, adding to a team with domain experience in rare disease clinical development, computational and medicinal chemistry, and business development
Read MoreMontreal’s My Intelligent Machines (aka MIMS) has raised a second seed round of financing in the amount of $5 million. According to Crunchbase, this is the company’s first raise since the fall of 2019 when it raised $2.6 million. This round was led by MEDTEQ+ and StandUp Ventures, with participation from Desjardins Capital, Anges Québec, Anges Québec Capital and Real Ventures.
Read MoreThe biotechnology and CRO industry issues 17 financing and public policy.
Read More